Provexis plc (AIM:PXS)

Market Cap	13.14M
Revenue (ttm)	1.20M
Net Income (ttm)	-478.29K
Shares Out	2.35B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,032,020
Average Volume	663,450
Open	0.520
Previous Close	0.553
Day's Range	0.550 - 0.625
52-Week Range	0.450 - 0.800
Beta	1.01
RSI	36.56
Earnings Date	Mar 28, 2025

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through company’s website a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2023, Provexis's revenue was 801,964, an increase of 105.68% compared to the previous year's 389,916. Losses were -586,243, 52.2% more than in 2022.